Full-Time

Quality Assurance Engineer

Contact Center & CRM Integrations

EVERSANA

EVERSANA

1,001-5,000 employees

Commercial services for pharmaceutical lifecycle management

No salary listed

Pune, Maharashtra, India

In Person

Category
QA & Testing (2)
,
Required Skills
Software Testing
Quality Assurance (QA)
Requirements
  • 3–5 years of QA or testing experience supporting enterprise technology platforms
  • Experience testing contact center solutions (cloud or on-prem), including voice or digital channels
  • Hands‑on experience testing system integrations, preferably between contact center platforms and CRM systems
  • Experience creating and executing test cases based on business and technical requirements
  • Familiarity with SDLC and QA practices in Agile or iterative delivery environments
  • Bachelor’s degree in Information Technology, Computer Science, Engineering, or a related field, or equivalent practical experience
Responsibilities
  • Develop and execute test strategies, test plans, and test cases for NICE contact center solutions, including voice, digital chat, messaging, omnichannel routing, and agent‑assist capabilities
  • Validate end‑to‑end customer and agent journeys across NICE and integrated CRM systems, ensuring correct data flow, context preservation, and workflow behavior
  • Perform functional, integration, regression, and release testing for NICE configurations, enhancements, and defect fixes
  • Test and validate CRM integrations with NICE, including screen pops, case creation, activity logging, data synchronization, and error handling
  • Verify handoffs between automation (Autopilot/Copilot), live agents, and CRM workflows to ensure seamless transitions and accurate context delivery
  • Identify, document, and track defects clearly and effectively, working with engineers to support resolution and retesting
  • Ensure that test results align with approved requirements, acceptance criteria, and business use cases
  • Support user acceptance testing (UAT) activities by assisting with test execution, issue validation, and release sign‑off readiness
  • Validate that all solutions meet quality, security, compliance, and performance expectations prior to production release
  • Maintain accurate QA documentation, including test artifacts and release validation evidence.All other duties as assigned
  • It is the policy of EVERSANA to provide reasonable accommodation when requested by an employee with a disability, unless such accommodation would cause an undue hardship for EVERSANA. If reasonable accommodation is needed to perform the essential functions of your job position, please contact Human Resources.

EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Milwaukee, Wisconsin

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Waltz Health merger creates direct-to-payer model disrupting traditional pharmacy benefits middlemen.
  • AI Agency Platform won 2026 Artificial Intelligence Excellence Award for agentic AI capabilities.
  • Recent executive hires (Guarino, Avram) bring Fortune 100 and agency expertise.

What critics are saying

  • Trinity acquisition of APACME advisory services eliminates regional revenue and market presence.
  • IQVIA's AI platform launch captures 20-30% of biotech launch contracts through scale.
  • Accredo specialty pharmacy expansion locks limited-distribution drugs, slashing rare disease margins 40%.

What makes EVERSANA unique

  • Integrated platform spans entire pharmaceutical lifecycle from launch to patient support.
  • Specialty pharmacy and direct dispensing capabilities enable data collection and patient adherence.
  • Serves 650+ organizations globally with 6,000 professionals across 25+ locations.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at EVERSANA who can refer or advise you

Benefits

Health Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PharmaLive
Feb 12th, 2026
EVERSANA names new chief legal officer

EVERSANA names new chief legal officer. EVERSANA has named Monica Avram as Executive Vice President and Chief Legal Officer, a strategic addition as the company scales operations and reinvents commercialization services. As Chief Legal Officer and a member of the Executive Leadership Team, Monica leads the company's global Legal and Compliance function. Her strategic leadership integrates governance, risk, and operational execution to enable innovation, strengthen enterprise performance, and drive long-term value. With more than two decades of experience at top law firms and across global Fortune 100 companies - including UnitedHealth Group and Sanofi - Avram brings deep expertise at the intersection of healthcare, law, and emerging technologies. She has built high-performing, financially disciplined legal teams, advised executive leadership and boards on enterprise strategy, and guided organizations through complex regulatory and operational environments. "As we continue to scale, it's paramount that we have top talent who can understand the complexity of our industry and bring proven track records of success," said Mark Thierer, CEO, EVERSANA. "Throughout her career, Monica has demonstrated exceptional leadership in building best-in-class legal organizations, and we're thrilled to welcome her to EVERSANA." She brings seasoned board and advisory experience across public companies and nonprofit organizations, with deep expertise in governance, oversight, and strategic leadership. Avram holds a BA in Biology from the University of Missouri - Kansas City and a Juris Doctor from Suffolk University Law School.

Business Wire
Nov 3rd, 2025
Trinity Acquires EVERSANA's APACME Services

Trinity has announced the acquisition of EVERSANA's advisory services operation in the Asia-Pacific and Middle East (APACME) regions. This strategic move will transition EVERSANA's APACME advisory services to Trinity, enhancing its global presence in life sciences commercialization solutions.

PR Newswire
Oct 23rd, 2025
OWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE(R)(lamotrigine) Oral Suspension

OWP Pharmaceuticals selects EVERSANA to support U.S. Launch of SUBVENITE(R)(lamotrigine) Oral Suspension. News provided by. CHICAGO, Oct. 23, 2025 /PRNewswire/ - OWP Pharmaceuticals, a privately held, commercial-stage neuroscience specialty pharmaceutical company, today announced that EVERSANA(R), a leading provider of commercialization services to the global life sciences industry, will provide U.S. commercialization services for the launch of SUBVENITE(R)(lamotrigine) oral suspension, the company's novel treatment for epilepsy and bipolar disorders. SUBVENITE(R), approved by the U.S. Food and Drug Administration on September 16, 2025, is the first and only FDA-approved lamotrigine oral suspension in the U.S. It is designed to help improve access to epilepsy treatments as a flexible, patient-friendly alternative to tablets. Lamotrigine is widely prescribed, but is now available in a ready-to-use liquid version. SUBVENITE(R) Oral Suspension is ideal for patients who have difficulty swallowing tablets, those who require individualized dosing, or prefer liquid medication formulations. To support a successful product launch, EVERSANA is currently activating an array of services, including field deployment, data & analytics, and co-pay services. The SUBVENITE(R) launch support is part of EVERSANA and OWP's broader commercialization partnership announced in January 2022. "Market access challenges continue to be the major hurdle for patients looking for new treatment options," said Gregory Skalicky, President, EVERSANA. "Together with OWP Pharmaceuticals, we're removing barriers and helping patients find new hope." OWP Pharmaceutical's commitment to innovation for patients expands beyond the United States. Since its founding in 2014, the company has developed a unique partnership with the ROW Foundation to support humanitarian efforts for people worldwide with epilepsy. As innovative new solutions like SUBVENITE become available, OWP is committed to ensuring it reaches patients in need, as nearly 80% of people with epilepsy live in underdeveloped countries, and about 75% of them do not have access to a treatment option. "Working with EVERSANA to support commercialization efforts in the U.S. is an important milestone for patients," said Scott Boyer, Founder and President, OWP Pharmaceuticals. "But our vision continues to be much larger, that every epilepsy patient globally one day might have access through OWP Pharma and ROW Foundation, the Pharmaceutical Social Enterprise(R). To learn more about OWP Pharmaceuticals, visit www.owppharma.com. About EVERSANA EVERSANA(R) is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X. About OWP Pharmaceuticals OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. Based in Lisle, IL, OWP is committed to advancing therapies in neurology and psychiatry, with a mission to bring meaningful innovations to patients. Through its partnership with the ROW Foundation, OWP also supports global initiatives to improve epilepsy care and education in underserved communities worldwide. For EVERSANA Matt Braun Vice President, Corporate Communications [email protected] SOURCE EVERSANA; OWP Pharmaceuticals

Arkansas Democrat-Gazette
Aug 27th, 2025
Eversana acquires Waltz Health

Eversana, a company that helps drugmakers sell their medicines, has acquired a smaller firm called Waltz Health that helps employers and health insurance companies purchase cheaper drugs, in a bid to build an alternative to traditional pharmacy benefits middlemen in the U.S.

PharmaLive
Aug 26th, 2025
EVERSANA Merges with Waltz Health

EVERSANA merges with Waltz Health.